Kiromic BioPharma's Total Assets for the quarter that ended in Mar. 2024 was $12.63 Mil.
During the past 12 months, Kiromic BioPharma's average Total Assets Growth Rate was -19.00% per year.
During the past 3 years, the average Total Assets Growth Rate was 49.60% per year.
During the past 5 years, the average Total Assets Growth Rate was 95.50% per year.
During the past 6 years, Kiromic BioPharma's highest 3-Year average Total Assets Growth Rate was 150.10%. The lowest was 49.60%. And the median was 121.90%.
The historical data trend for Kiromic BioPharma's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Kiromic BioPharma's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kiromic BioPharma (OTCPK:KRBP) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Mar. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Kiromic BioPharma's Asset Turnover for the quarter that ended in Mar. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Kiromic BioPharma Total Assets Related Terms
Thank you for viewing the detailed overview of Kiromic BioPharma's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Kiromic BioPharma (Kiromic BioPharma) Business Description
Kiromic BioPharma Inc is a biotechnology company. It is an artificial intelligence (AI) driven, end-to-end allogeneic cell therapy company, currently developing the multi-indication allogeneic T cell therapy that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company is a gene-editing which utilizes artificial intelligence and a proprietary neural network platform with a therapeutic focus on immuno-oncology.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
KRBP has been successfully added to your 